O.28Safety and tolerability of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy: results from a phase 1 clinical trial
Kathryn R. Wagner(Kennedy Krieger Institute), Michael Panzara, M. Eagle, Teresa Gidaro(Center for Neurosciences), Linda Cripe(The Ohio State University), Volker Straub(Newcastle upon Tyne Hospitals NHS Foundation Trust), Laurent Servais(University of Oxford), Francesco Muntoni(National Institute for Health and Care Research), Xiao Hu(Wave Life Sciences (United States)), H. Phan(Rare Disease Therapeutics (United States)), Stephen Lake(Boston University), Pallavi Lonkar(Wave Life Sciences (United States)), Shu‐Fang Hsu Schmitz(Wave Life Sciences (United States))
Cited by 4
Related Papers
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
|The Lancet Neurology|2009|2k
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
|The Lancet Neurology|2009|1.2k
Improving genetic diagnosis in Mendelian disease with transcriptome sequencing
|Science Translational Medicine|2017|809
A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
|Annals of Neurology|2008|466